SELLAS Life Sciences receives $23.6 million from warrant exercise

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. SPCX
2. LEVI
3. SBUX
4. NVDA
5. GOOGL
6. SPY
7. APLD
8. ORCL
9. USO
10. STZ

Go back to SELLAS Life Sciences receives $23.6 million from warrant exercise

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds

September 11, 2025 8:30 AM EDT

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (SELLAS or the Company), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the immediate exercise of warrants, previously issued in January 2025, to purchase up to 19,685,040 shares of its common stock for gross cash proceeds of approximately $23.6 million.

In consideration for the immediate exercise in full of the warrants issued in January 2025, the investor will receive, in a private placement, new unregistered warrants to purchase... More